Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Grifols SA, operating under the ticker GRF, is a biopharmaceutical company specialized in the production of plasma-derived medicines. Founded in 1940 and headquartered in Barcelona, Spain, Grifols is engaged in the diagnosis, prevention, and treatment of a variety of diseases, with a strong focus on immunology, hematology, and intensive care sectors. The company operates globally, leveraging advanced technologies and rigorous quality processes to provide essential medical products.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Grifols Class AJohnson & Johnson
Last price
€9.87$254.78
Currency
EUR
USD
€5.7B$610B
14.3929.32
€0.66$8.63
1.190.23
€0.07$5.28
0.70%2.12%
Sector
HealthHealth
Employees
25,258138,200
Ticker
€GRF$JNJ
Primary listing
BMENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €GRF or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.